Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael S Kolodney

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Journal of the American Academy of Dermatology|June 1, 2025
Response to "Characterizing immune checkpoint inhibitor-associated Stevens-Johnson syndrome and toxic epidermal necrolysis: Caution advised"Michael S Kolodney
Journal of the American Academy of Dermatology|December 28, 2020
Reply to letter to the editor: "A response to 'Male balding is a major risk factor for severe COVID-19'"Ahmed Yousaf, Michael S Kolodney
Journal of the American Academy of Dermatology|April 29, 2005
Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximabMarvi Iqbal, Michael S Kolodney
Journal of the American Academy of Dermatology|March 2, 2025
Retrospective cohort study characterizing the association of xanthelasmas with cardiovascular risk factors and outcomesWade Powers, Michael S Kolodney
The Journal of Investigative Dermatology|September 19, 2021
GWAS Identifies Three Susceptibility Loci for Trichilemmal CystsAhmed Yousaf, Michael S Kolodney
Oncogene|August 24, 2005
Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimensPatrick L Dominguez, Michael S Kolodney
Journal of the American Academy of Dermatology|June 30, 2025
Response to "Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of immune checkpoint inhibitors: A disproportionality analysis using the FDA Adverse Event Reporting System database"Michael S Kolodney, Joanna A Kolodney
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|May 10, 2006
Mesotherapy and phosphatidylcholine injections: historical clarification and reviewAdam M Rotunda, Michael S Kolodney
Journal of the American Academy of Dermatology|May 16, 2025
Fournier's Gangrene After Starting Glucose Lowering Medications: A retrospective cohort studyMichael S Kolodney, Iraj Hasan, Olivia Lim
Journal of the American Academy of Dermatology|February 11, 2023
Tumor necrosis factor inhibitors and methotrexate are associated with decreased COVID-19-related hospitalization: Follow up of "Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors and methotrexate"Rachel Tallman Cahn, Zachary Zinn, Michael S Kolodney
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Journal of the American Academy of Dermatology|June 1, 2025
Response to "Characterizing immune checkpoint inhibitor-associated Stevens-Johnson syndrome and toxic epidermal necrolysis: Caution advised"Michael S Kolodney
Journal of the American Academy of Dermatology|December 28, 2020
Reply to letter to the editor: "A response to 'Male balding is a major risk factor for severe COVID-19'"Ahmed Yousaf, Michael S Kolodney
Journal of the American Academy of Dermatology|April 29, 2005
Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximabMarvi Iqbal, Michael S Kolodney
Journal of the American Academy of Dermatology|March 2, 2025
Retrospective cohort study characterizing the association of xanthelasmas with cardiovascular risk factors and outcomesWade Powers, Michael S Kolodney
The Journal of Investigative Dermatology|September 19, 2021
GWAS Identifies Three Susceptibility Loci for Trichilemmal CystsAhmed Yousaf, Michael S Kolodney
Oncogene|August 24, 2005
Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimensPatrick L Dominguez, Michael S Kolodney
Journal of the American Academy of Dermatology|June 30, 2025
Response to "Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of immune checkpoint inhibitors: A disproportionality analysis using the FDA Adverse Event Reporting System database"Michael S Kolodney, Joanna A Kolodney
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|May 10, 2006
Mesotherapy and phosphatidylcholine injections: historical clarification and reviewAdam M Rotunda, Michael S Kolodney
Journal of the American Academy of Dermatology|May 16, 2025
Fournier's Gangrene After Starting Glucose Lowering Medications: A retrospective cohort studyMichael S Kolodney, Iraj Hasan, Olivia Lim
Journal of the American Academy of Dermatology|February 11, 2023
Tumor necrosis factor inhibitors and methotrexate are associated with decreased COVID-19-related hospitalization: Follow up of "Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors and methotrexate"Rachel Tallman Cahn, Zachary Zinn, Michael S Kolodney
Pageof 5